Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2009

01-12-2009 | Original Paper

Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience

Authors: Orhan Onder Eren, Mehmet Artac, Melih Cem Boruban, Ozlem Yavas, Ugur Arslan, Metin Basaranoglu

Published in: Medical Oncology | Issue 4/2009

Login to get access

Abstract

Hepatitis B reactivation due to chemotherapy is a cause of serious morbidity and mortality in some of the patients with cancer. In this study, we retrospectively assessed the prevalence of hepatitis B reactivation among the patients undergoing cytotoxic chemotherapy. We investigated efficacy of lamivudine prophylaxis against hepatitis B reactivation as well.
Literature
1.
2.
3.
Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299–307. doi:10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0.CrossRefPubMed
4.
Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–8.PubMed
5.
6.
7.
Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;246:540–6.CrossRef
8.
Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37(10):705–12.PubMed
9.
Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer. 1999;81(1):69–74. doi:10.​1038/​sj.​bjc.​6690652.CrossRefPubMed
10.
11.
Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation inpatients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83(5):270–5. doi:10.​1007/​s00277-003-0825-8.CrossRefPubMed
12.
13.
Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma. Ann Oncol. 1998;9(4):385–7. doi:10.​1023/​A:​1008206519571.CrossRefPubMed
14.
Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306–11. doi:10.​1038/​sj.​bjc.​6601699.CrossRefPubMed
15.
Hsu CH, Hsu HC, Chen HL, et al. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res. 2004;24(5A):3035–40.PubMed
16.
17.
18.
Gish RG, Locarnini S. Studying the treatment of chronic hepatitis B viral infection in special populations. Methods Mol Med. 2004;96:465–98.PubMed
19.
20.
Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer. 1996;78(10):2210–5. doi:10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0.CrossRefPubMed
21.
Cheng AL, Hsiung CA, Su IJ, et al. Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37(6):1320–8. doi:10.​1053/​jhep.​2003.​50220.CrossRefPubMed
22.
23.
Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17(1):394–8.PubMed
24.
Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol. 2001;65(3):473–7. doi:10.​1002/​jmv.​2060.CrossRefPubMed
25.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Panel members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16(10):1569–83. doi:10.​1093/​annonc/​mdi326.CrossRefPubMed
26.
27.
Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer. 2004;12(3):191–6. doi:10.​1007/​s00520-003-0549-2.CrossRefPubMed
28.
Cheng JC, Liu MC, Tsai SY, Fang WT, Jer-Min Jian J, Sung JL. Unexpectedly frequent hepatitis B reactivation by chemoradiation in postgastrectomy patients. Cancer. 2004;101(9):2126–33. doi:10.​1002/​cncr.​20591.CrossRefPubMed
29.
Macdonald JS, Smalley SR, Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30. doi:10.​1056/​NEJMoa010187.CrossRefPubMed
30.
31.
32.
Idilman R. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut. 2006;55(8):1208–9.PubMed
33.
Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15(2):89–102.PubMed
34.
Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519–28.PubMed
Metadata
Title
Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience
Authors
Orhan Onder Eren
Mehmet Artac
Melih Cem Boruban
Ozlem Yavas
Ugur Arslan
Metin Basaranoglu
Publication date
01-12-2009
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 4/2009
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9133-4

Other articles of this Issue 4/2009

Medical Oncology 4/2009 Go to the issue

Case Report

A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection

Original Paper

Frequency of FLT3 mutations in childhood acute lymphoblastic leukemia

Original Paper

An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase

Original Paper

Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection

Original Paper

Lung carcinoma mimicking hydatid cyst: a case report and review of the literature

Original Paper

Proteinase-activated receptor-1 mediates allogeneic CD8+ T cell-induced apoptosis of vascular endothelial cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits